Skip to main content

Table 2 Baseline characteristics of patients who failed to achieved SVR12

From: Efficacy and safety of sofosbuvir and daclatasvir in patients with chronic hepatitis C virus induced cirrhosis with Child-Pugh class B

Parameter Non-responders
N = 3
Relapsers
N = 3
Discontinued due to adverse events
N = 9
P value
Age (years)
 Mean ± SD 56.33 ± 6.66 51.33 ± 8.13 60.44 ± 6.24 0.18
  (Min–Max) (49–62) (41–61) (52–70)
Gender
 Male 1(33.3%) 2(66.7%) 6(66.7%) 0.57
 Female 2(66.7%) 1(33.3%) 3(33.3%)
Prior HCV treatment
 Naïve 2(66.7%) 3(100%) 7(77.8%) 0.57
 Experienced 1(33.3%) 0(0%) 2(22.2%)
Laboratory data
 Hemoglobin (gm/dl) 13.3 ± 2.3 12.73 ± 1.11 11.36 ± 1.32 0.14
 Male: (13.2–17.5 gm/dl)     
 Female: (11.5–16 gm/dl)     
WBCs × 103/ml (4–11 × 103/ml) 3.3 ± 0.36 5.7 ± 2.1 3.26 ± 1.12 0.035
Platelet count × 103/ml (150–450 × 103/ml) 58 (58–100) 84 (74–111) 111 (55–142) 0.33
PCR (IU/ml) × 103 4780 (216.218–4823) 1210 (393–1490) 429 (10.780–1603.390) 0.19
ALT/ULN (fold) 1.05 (0.78–4.12) 1.03 (0.8–1.24) 0.93 (0.48–2.85) 0.49
AST/ULN (fold) 1.62 (1.03–4.7) 1.85 (1.38–3.41) 1.73 (0.4–3.46) 0.91
Serum albumin (g/dl) (3.4–5.4 g/dl) 3 ± 0.26 2.53 ± 0.25 2.8 ± 0.24 0.10
Serum bilirubin (mg/dl) (0.3–1 mg/dl) 1.77 ± 0.6 2.3 ± 0.79 1.54 ± 1 0.48
I.N.R. (0.9–1.2) 1.42 ± 0.28 1.42 ± 0.14 1.3 ± 0.18 0.53
Serum creatinine (mg/dl)
 Male: (0.6–1.2 mg/dl) 0.6 ± 0.1 0.87 ± 0.4 1.17 ± 0.4 0.09
 Female: (0.8–1.4 mg/dl)     
AFP (μg/l) (< 8 μg/l) 12 (6.5–83) 10.2 (9–20.7) 7.6 (2.64–25) 0.37
MELD score
 Median 12 14 13  
  (Min–max) (11–13) (11–17) (8–18) 0.62
 < 10 0(0%) 0(0%) 2(22.2%) 0.46
 ≥ 10 3(100%) 3(100%) 7(77.8%)  
Ultrasonographic features
 Liver cirrhosis 3(100%) 3(100%) 9(100) P = 1.0
 Splenomegaly 1(33.3%) 1(33.3%) 4(44.4%) P = 0.9
 Ascites 1(33.3%) 1(33.3%) 9(100%) P = 0.02
 Hemangioma 1(33.3%) 0(0%) 0(0%) P = 0.12
 Ablated HCC 0(0%) 0(0%) 0(0%)  
Child-Pugh score
 B7 3(100%) 1(33.3%) 2(22.2%) 0.19
 B8 0(0%) 1(33.3%) 5(55.6%)  
 B9 0(0%) 1(33.3%) 2(22.2%)